カテゴリ： GlobalData, アメリカ, 企業調査

CTI BioPharma Corp (CTIC)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：CTI BioPharma Corp (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012239
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：87
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in Europe and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp (CTIC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cell Therapeutics Acquires Pacritinib From S*BIO 11
Venture Financing 13
CTI BioPharma Announces Venture Debt Financing 13
Licensing Agreements 14
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
Equity Offering 17
CTI BioPharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 18
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 20
CTI BioPharma Raises USD50 Million in Public Offering of Shares 22
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 24
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 26
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 28
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 29
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 31
Cell Therapeutics Completes Private Placement Of Series 14 Preferred Stock For US$20 Million 33
Cell Therapeutics Completes Private Placement Of Series 13 Preferred Stock For US$30 Million 34
Cell Therapeutics Completes Private Placement Of Series 12 Preferred Stock For US$16 Million 36
Cell Therapeutics Completes Private Placement Of US$25 Million 38
Cell Therapeutics Completes Registered Offering Of US$25 Million 40
CTI BioPharma Corp – Key Competitors 42
CTI BioPharma Corp – Key Employees 43
CTI BioPharma Corp – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
Nov 06, 2017: CTI BioPharma Reports Third Quarter 2017 Financial Results 45
Aug 03, 2017: CTI BioPharma Reports Second Quarter 2017 Financial Results 47
May 03, 2017: CTI BioPharma Reports First Quarter 2017 Financial Results 48
Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 49
Nov 08, 2016: CTI BioPharma Reports Third Quarter 2016 Financial Results 51
Aug 04, 2016: CTI BioPharma Reports Second Quarter 2016 Financial Results 52
May 10, 2016: CTI BioPharma Reports First Quarter 2016 Financial Results 53
Feb 16, 2016: CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results 54
Corporate Communications 56
Sep 26, 2017: CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions 56
Jul 24, 2017: CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors 57
Jun 05, 2017: CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations 58
Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 59
Oct 03, 2016: CTI BioPharma Announces Retirement Of President And CEO 60
Jan 13, 2016: CTI BioPharma Appoints Matthew Perry To Board Of Directors 61
Product News 62
Dec 01, 2016: CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 62
05/19/2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting 63
04/13/2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting 64
01/09/2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017 66
Product Approvals 68
Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) 68
Feb 09, 2016: CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S. 69
Feb 08, 2016: CTI BioPharma Provides Update On Investigational Agent Pacritinib 70
Jan 05, 2016: CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet Medical Need In Myelofibrosis 71
Clinical Trials 72
Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 72
Dec 06, 2016: PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting 74
Nov 21, 2016: CTI BioPharma Announces data on Pacritinib at ASH Annual Meeting 76
Aug 29, 2016: CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis 78
Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting 80
Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment 83
Other Significant Developments 85
Jan 11, 2016: CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016 85
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CTI BioPharma Corp, Deals By Therapy Area, 2011 to YTD 2017 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cell Therapeutics Acquires Pacritinib From S*BIO 11
CTI BioPharma Announces Venture Debt Financing 13
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
CTI BioPharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 18
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 20
CTI BioPharma Raises USD50 Million in Public Offering of Shares 22
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 24
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 26
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 28
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 29
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 31
Cell Therapeutics Completes Private Placement Of Series 14 Preferred Stock For US$20 Million 33
Cell Therapeutics Completes Private Placement Of Series 13 Preferred Stock For US$30 Million 34
Cell Therapeutics Completes Private Placement Of Series 12 Preferred Stock For US$16 Million 36
Cell Therapeutics Completes Private Placement Of US$25 Million 38
Cell Therapeutics Completes Registered Offering Of US$25 Million 40
CTI BioPharma Corp, Key Competitors 42
CTI BioPharma Corp, Key Employees 43
CTI BioPharma Corp, Subsidiaries 44

★海外企業調査レポート[CTI BioPharma Corp (CTIC)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Qassim Cement Company：企業の戦略・SWOT・財務情報
    Qassim Cement Company - Strategy, SWOT and Corporate Finance Report Summary Qassim Cement Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hell Pizza：企業の戦略・SWOT・財務分析
    Hell Pizza - Strategy, SWOT and Corporate Finance Report Summary Hell Pizza - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • DIC Corp (4631)：企業の財務・戦略的SWOT分析
    DIC Corp (4631) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Australian Mines Limited：企業の戦略・SWOT・財務分析
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CanBas Co Ltd (4575)-製薬・医療分野：企業M&A・提携分析
    Summary CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that provides drugs. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It product under development is CBP501, a modified synthetic peptide enhancing the efficacy of …
  • athenahealth Inc (ATHN)：製薬・医療：M&Aディール及び事業提携情報
    Summary athenahealth Inc (athenahealth) is a provider of cloud-based business services and mobile applications for medical groups and health system. The company offers network-enabled services for revenue cycle management and medical billing, electronic health records (EHR), patient engagement, popu …
  • Jadranski naftovod dd (JNAF-R-A)：企業の財務・戦略的SWOT分析
    Summary Jadranski naftovod dd (JANAF Plc) is an oil pipeline system managing company that operates crude oil transportation system and reloading and storage of crude oil and oil products. The company manages janaf system, an international crude oil transportation system. Its janaf systems consists o …
  • CITIC Securities Company Limited：企業の戦略・SWOT・財務情報
    CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • PDL BioPharma Inc (PDLI)：製薬・医療：M&Aディール及び事業提携情報
    Summary PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions …
  • Arbuthnot Latham & Co., Limited：企業の戦略・SWOT・財務情報
    Arbuthnot Latham & Co., Limited - Strategy, SWOT and Corporate Finance Report Summary Arbuthnot Latham & Co., Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • JCDecaux SA：企業の戦略・SWOT・財務情報
    JCDecaux SA - Strategy, SWOT and Corporate Finance Report Summary JCDecaux SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Erasmus MC-製薬・医療分野：企業M&A・提携分析
    Summary Erasmus MC (Erasmus) is a medical institute that offers patient care, research and educational services. The institute offers graduate and doctoral programs in health sciences, biomedical sciences, molecular medicine and cardiovascular sciences. It conducts research in the areas of biochemis …
  • Sprott Resource Holdings Inc. (SRHI)：企業の財務・戦略的SWOT分析
    Sprott Resource Holdings Inc. (SRHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ryanair Holdings Plc (RY4C)：企業の財務・戦略的SWOT分析
    Ryanair Holdings Plc (RY4C) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kasbah Resources Limited：戦略・SWOT・企業財務分析
    Kasbah Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Kasbah Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hycrete Inc：企業の戦略的SWOT分析
    Hycrete Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Piramal Glass Ltd：企業の戦略・SWOT・財務情報
    Piramal Glass Ltd - Strategy, SWOT and Corporate Finance Report Summary Piramal Glass Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Motiva Enterprises LLC：企業の戦略・SWOT・財務情報
    Motiva Enterprises LLC - Strategy, SWOT and Corporate Finance Report Summary Motiva Enterprises LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Fondazione Telethon：製薬・医療：M&Aディール及び事業提携情報
    Summary Fondazione Telethon (Telethon) is a non-profit healthcare organization that funds and invests for projects in the area of biomedical research on genetic diseases. The organization develops projects by offering support services for increasing the horizons of therapeutic application to new res …
  • SpringWorks Therapeutics LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary SpringWorks Therapeutics LLC (SpringWorks Therapeutics) is a drug development company that develops therapeutic medicines for various diseases. The company’s pipeline products include Nirogacestat, MEK ½ Inhibitor, Senicapoc and FAAH Inhibitor. Its Nirogacestat is a gamma secretase inhibitor …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆